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Renal ischemia/reperfusion injury is a major complication
of kidney transplantation. We tested if ex vivo delivery of
carbon monoxide (CO) to the kidney would ameliorate
the renal injury of cold storage that can complicate renal
transplantation. Orthotopic syngeneic kidney transplantation
was performed in Lewis rats following 24 h of cold
preservation in University of Wisconsin solution equilibrated
without or with CO (soluble CO levels about 40 lM). Ischemia/
reperfusion injury in control grafts resulted in an early
upregulation of inflammatory mediator mRNAs and
progressive deterioration of graft function. In contrast, the
grafts preserved with CO had significantly less oxidative
injury and this was associated with improved recipient
survival compared to the control group. Renal injury in
the control group showed considerable degradation of
cytochrome P450 heme proteins, active heme metabolism
and increased detrimental intracellular free heme levels.
Kidney grafts preserved in CO-equilibrated solution
maintained their cytochrome P450 protein levels, had normal
intracellular heme levels and had less lipid peroxidation.
Our results show that CO-mediated suppression of injurious
heme-derived redox reactions offers protection of kidney
grafts from cold ischemia/reperfusion injury.
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Currently, kidney transplantation (KTx) is widely practiced
around the world and has been accepted as the preferred
strategy of renal replacement therapy for end-stage renal
disease. However, ischemia/reperfusion (I/R) injury due to
cold storage and warm reoxygenation, obligatory to KTx
procedure, remains unfavorable factor in KTx, contributing
to delayed graft function and subsequent chronic graft
deterioration.1,2
Recent evidences have implicated that cytochrome P450
(CYP), a large group of heme proteins abundantly present in
the kidney, play critical roles in the renal I/R injury
process.3–5 CYPs are susceptible to oxidant stress and
substantially damaged during renal I/R injury by reactive
oxygen species (ROS) such as superoxide anion and hydrogen
peroxide. Damaged CYPs are prone to degrade and release
free heme/iron.5–9 Although heme is an essential molecule for
the living aerobic organisms as the prosthetic subunit of
heme proteins to maintain cellular viability in various
biological reactions,10 free heme released from heme proteins
during hemorrhage, hemolysis, or cell damages is highly
lipophilic and detrimental. It can directly induce tissue injury
by rapidly promoting peroxidation of the lipid membranes of
the cells.11,12 In addition, intracellular free heme can be a
major source of iron, which participates in the generation of
more detrimental hydroxyl radicals from hydrogen peroxide
via Fenton reaction, or becomes highly reactive iron–oxygen
complexes such as ferryl or perferryl ion.13,14 Thus, CYP
degradation and increased intracellular free heme due to
renal I/R injury could play a significant role in the renal graft
damage.
Accordingly, the strategies to inhibit CYP degradation and
subsequent heme/iron release will have a substantial effect in
ameliorating I/R injury and improve renal transplant
outcomes. Carbon monoxide (CO) possesses a strong affinity
to heme moiety of heme proteins15,16 and could alter the
biological behaviors of CYPs,17,18 as the binding of nitric
oxide inhibits the biological action of CYP4A219 and CYP
omega-hydroxylase.20 We hypothesized that the binding of
CO to renal CYP would stabilize CYP, and prevent CYP
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degradation and detrimental heme/iron release in renal
grafts, leading to potent protection of kidney grafts from
I/R injury. We have tested our hypothesis in this study
using the orthotopic rat KTx model with 24 h cold
preservation. CO was mixed into UW preservation solu-
tion and ex vivo delivered to excised kidney grafts during
cold preservation and before transplantation. Our data
provide a novel mechanism of the protective effects of
ex vivo organ-targeted CO delivery against transplant-
induced I/R injury.
RESULTS
Tissue CO content elevated by ex vivo organ-targeted CO
delivery protocol
CO solubility in UW solution elevated to 40.6±1.6 mmol/l
after CO supplementation from 0.7±0.6 mmol/l in untreated
UW solution.21 When kidney grafts were perfused with and
stored in CO-bubbled UW, tissue CO contents at the end
of 24 h cold preservation elevated to 23.3±4.2 pmol/mg
tissue, whereas the grafts stored in control UW showed
1.43 pmol/mg tissue. These results demonstrate that CO gas
can be effectively delivered to kidney grafts during cold
storage before transplantation using ex vivo organ-targeted
CO delivery protocol. However CO levels of the grafts stored
in both control UW and UW with CO 3 h after reperfusion
were basal levels, indicating that CO quickly disappeared
from the grafts within 3 h after reperfusion (Figure 1a).
CO prevented CYP degradation during I/R injury
Total CYP contents in the microsomal fraction of the grafts
were determined at the end of cold storage and 3 h after
KTx. Graft CYP contents were maintained throughout the
cold storage period and the levels at the end of cold storage
were similar to those of naive kidneys. Total CYP contents,
however, were significantly decreased in the kidney grafts
preserved in control UW at 3 h after KTx. On the other
hand, the kidney grafts stored in UW with CO maintained a
nearly normal concentration of CYP at the same time point
(Figure 1b). These data indicate that ex vivo organ-targeted
CO delivery during cold storage prevents CYP breakdown
during I/R process.
CO reduced heme content in the grafts during I/R injury
As degraded CYP during I/R injury possibly become the
source of detrimental intracellular free heme, microsomal
heme contents in the kidney grafts were assessed 3 h after
reperfusion. Microsomal heme content elevated significantly
in the grafts stored in control UW. Ex vivo organ-targeted
CO delivery protocol significantly decreased intracellular free
heme concentration (Figure 1c).
CO delivery reduced upregulation of mRNA for heme
synthesis enzyme 5-aminolevulinate synthase
Although heme plays an essential role in the body as a
component of heme proteins, intracellular free heme is
injurious. Therefore, heme concentration in the cell is tightly
controlled mostly via heme biosynthesis rate-limiting en-
zyme, 5-aminolevulinate synthase (ALAS-1).22,23 We there-
fore examined sequential changes of graft mRNA levels for
ALAS-1 using northern blot analysis. In the control UW
group, ALAS-1 mRNA levels in the kidney grafts were
markedly suppressed at 3 h after reperfusion, and gradually
increased to the normal level by 6 h (Figure 2a). The decrease
of ALAS-1 mRNA levels in the control UW group at 3 h was
significantly inhibited in UW with the CO group (Figure 2b).
These results indicate that increased microsomal heme levels
in I/R injury in the control UW group coincidently
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Figure 1 | Concentrations of CO, CYP and heme in the graft.
(a) Tissue CO content. Ex vivo organ-targeted CO delivery resulted
in an elevation of tissue CO levels in kidney grafts at the end of
the cold storage (CS) for 24 h in UW containing CO (COUW).
Normal control kidney and kidney grafts stored in control UW
showed negligible CO levels. CO contents in the grafts stored in
COUW returned to basal levels within 3 h after kidney
transplantation (KTx; Ctl: normal control kidney; black bar: grafts
stored in control UW; gray bar: grafts stored in COUW; *Po0.05 vs
UW; n¼ 4–5). (b) Tissue total cytochrome P450 (CYP) contents.
Tissue CYP contents were maintained during cold storage at
similar levels of normal controls. CYP levels dramatically reduced
3 h after reperfusion in kidney grafts stored in control UW.
Preservation of kidney grafts in COUW for 24 h prevented
a loss of CYP at 3 h after reperfusion (*Po0.05 vs UW; n¼ 4–6).
(c) Tissue microsomal heme contents. Intracellular heme
concentration elevated at 3 h after reperfusion of kidney grafts
stored in control UW. CO significantly reduced tissue heme
contents (*Po0.05 vs UW; n¼ 5–6).
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downregulate heme biosynthesis due to negative feedback
mechanism, whereas CO in the UW group maintains normal
heme biosynthesis. In addition, these results also reveal that
increased intracellular heme contents during renal I/R injury
are not caused by accelerated heme biosynthesis, but heme
release from degraded heme proteins such as CYP. Further,
the inhibition of heme elevation with CO is not due to
ALAS-1 downregulation.
CO decreased heme oxygenase-1 expression in the kidney
grafts
Conversely, we assessed the activation of heme-degrading
enzyme heme oxygenase-1 (HO-1), which plays a primary
role to eliminate toxic free heme and to protect cells from
heme-induced oxidative stress.12 HO-1 mRNA levels in the
kidney grafts rapidly elevated after reperfusion and peaked at
3 h in the control UW group. CO significantly inhibited
intragraft HO-1 mRNA upregulation. Cold storage in control
UW or UW containing CO did not alter graft HO-1 mRNA
expression (Figure 3a). In correlation with mRNA levels,
HO-1 protein levels gradually increased after reperfusion and
were markedly increased 6 h after reperfusion (Figure 3b).
CO in UW significantly reduced HO-1 protein levels in the
graft 6 h after reperfusion (Figure 3c). These data reveal that
an increase of intracellular heme in renal I/R injury triggers
the induction of heme catalytic enzyme, HO-1.24,25
CO reduced oxidative injury in the kidney grafts
The magnitude of the graft oxidative injury was determined
by measuring tissue malondialdehyde (MDA) level. MDA is
the most abundant byproduct of lipid peroxidation caused by
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Figure 2 | ALAS-1 expression in the graft. (a) Sequential analysis
of mRNA levels for 5-aminolevulinate synthase (ALAS-1) in control
kidney grafts. Kidney grafts stored in control UW showed marked
suppression of ALAS-1 mRNA at 3 h after reperfusion and
subsequent gradual recovery to the normal levels. Pictures for
autoradiographic signals for ALAS-1 and ethidium bromide stain
for loading controls (28S and 18S) are representative from two
independent northern blot experiments. ALAS-1 mRNA band
intensity was quantified by the ratio to 18S band intensity
(*Po0.05 vs UW; n¼ 3–4). (b) ALAS-1 mRNA levels at 3 h after
reperfusion. ALAS-1 mRNA levels were significantly higher in
kidney grafts stored in UW containing CO (COUW) than in control
UW at 3 h after reperfusion. The former showed nearly normal
ALAS-1 mRNA levels. Band intensity was quantified as the relative
band intensity compared to 18S band (*Po0.05 vs UW; n¼ 3).
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Figure 3 | HO-1 expression in the graft. (a) Sequential analysis of
heme oxygenase-1 (HO-1) mRNA. Real-time RT-PCR demonstrated
that HO-1 mRNA rapidly elevated and peaked at 3–6 h after
reperfusion of kidney grafts stored in control UW. CO significantly
decreased HO-1 mRNA upregulation in kidney grafts preserved in
UW containing CO (*Po0.05 vs UW; n¼ 3–5). (b) HO-1 Protein
expression in control kidney grafts. Western blot revealed gradual
increase of HO-1 protein expression in kidney grafts stored in
control UW. Representative picture from two independent
experiments using four samples was shown (Ctl: normal control
kidney). (c) HO-1 protein expression at 6 h after reperfusion. HO-1
protein expression at 6 h in kidney grafts stored in control UW was
significantly higher compared to that in kidney grafts stored in
UW containing CO (COUW). Representative picture from two
independent western blots using 4–5 samples was shown. The
band densities were measured by NIH Image analysis software
and presented in comparison to relative actin band (*Po0.05 vs
UW; n¼ 4–5).
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ROS generated during I/R injury. Graft MDA levels did not
change during cold storage and were maintained at the basal
level. However, MDA levels in the grafts stored in control UW
significantly elevated and peaked at 3 h after reperfusion.
Supplementation of CO into UW resulted in a significant
reduction of MDA levels in the grafts 3 h after reperfusion,
suggesting that CO given during cold storage reduced
injurious ROS and inhibited cellular lipid peroxidation
associated with I/R injury (Figure 4a).
CO reduced mRNA expression for inflammatory mediators
Both CYP-derived free heme and catalytic iron-derived ROS,
generated during I/R injury, may participate in direct
oxidative damage of graft parenchymal cells. Sequential
expression of inflammatory mediators including cyclooxy-
genase-2 (COX-2), interleukin-6 (IL-6), tumor necrosis
factor-a (TNFa), and early growth response-1 (Egr-1) were
examined. Graft mRNA levels for these mediators rapidly
elevated and peaked at 3 h after KTx. CO in UW effectively
downregulated I/R-induced activation of inflammatory
mediators in the kidney grafts (Figure 4b).
CO reduced histopathological changes
Prolonged cold storage of the grafts in control UW for 24 h
resulted in tubular atrophy, cellular infiltration, and mild
glomerulitis at 28 days after KTx. These histopathological
changes were less severe in the grafts stored in UW with CO
(Figure 5a). Glomerulosclerosis or vasculitis was not seen in
the grafts in either group. A number of ED1þ infiltrating
macrophages in control grafts was increased to 55.2±16.2
cells per high power field (HPF) compared to 29.7±11.8 cells
per HPF in naive kidneys. The grafts stored in CO-treated
UW showed significantly reduced number of ED1þ
infiltrating macrophages (Figure 5b).
CO ameliorated renal failure following I/R injury
Cold I/R injury resulted in progressive deterioration of renal
graft function, and creatinine clearance (CCr) dramatically
decreased to 0.28±0.11 ml/min at 28 days after KTx, which
was less than 12% of that seen in normal animals.
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Figure 4 | Oxidative injuries of the graft. (a) Graft
malondialdehyde (MDA) levels. Reperfusion of the control grafts
stored in control UW resulted in rapid increase of tissue MDA
levels in the grafts at 3 h after reperfusion. Tissue MDA levels were
significantly lower in kidney grafts stored in UW containing CO
(COUW) compared to those in control UW at 3 h after reperfusion
(CS: cold storage; KTx: kidney transplantation; *Po0.05 vs UW;
n¼ 4). (b) mRNA levels for inflammatory mediators. Real-time
RT-PCR showed rapid upregulations of cyclooxygenase-2 (COX-2),
interleukin-6 (IL-6), tumor necrosis factor-a (TNFa), and early
growth response-1 (Egr-1) mRNA in kidney grafts preserved in
control UW 3 h after reperfusion. CO significantly reduced the
peak mRNA levels for these inflammatory mediators (*Po0.05 vs
UW; n¼ 4–5).
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Figure 5 | Histopathological analysis. (a) Representative
histopathological images of syngeneic kidney grafts with
prolonged cold ischemia 28 days after kidney transplantation
(KTx). The grafts stored in control UW showed massive cellular
infiltrates and tubular atrophy. CO reduced these histological
changes at the same time points (original magnification,  200).
(b) A number of ED1þ macrophages were seen in the interstitial
area of the grafts stored in control UW 28 days after KTx.
Preservation in UW containing CO (COUW) significantly reduced
macrophage infiltration. Data were presented as number of
positive cells per high power field (HPF; n¼ 4; *Po0.05 vs
control UW).
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Furthermore, whereas normal animals excreted small
amounts of urine protein (0.2 mg per 24 h), the grafts in
control UW showed significant proteinuria (155.3±41.7 mg
per 24 h) at 28 days after KTx. When kidney grafts were
preserved for 24 h in 5% CO-bubbled UW, graft functions
at 28 days after KTx were significantly improved (CCr:
0.64±0.26 ml/min; proteinuria: 96.7±25.4 mg per 24 h)
compared to those of control UW (Figure 6a and b). Mean
body weight gains at 28 days after KTx in the recipients of
control UW group and CO-treated UW group were 3.42
and 9.01%, respectively (Figure 6c). In correlation to
improved renal functions, ex vivo organ-targeted CO delivery
significantly enhanced recipient survival to a median of
4100 days, compared to 51 days of control UW group
(Figure 6d). The recipients in both control UW and UW with
CO groups showed high levels of serum creatinine
(7.9–9.0 mg per 100 ml), potassium (6.5–8.9 mEq/l), and urea
nitrogen (481–789 mg per 100 ml) at their terminal phase. At
autopsy, these recipients did not have any surgical complica-
tion or other abnormality.
DISCUSSION
Increasing evidences have demonstrated that inhalation of
CO at low concentrations (20–500 p.p.m.) prevents I/R injury
in various experimental organ transplantation models.26–29
Although inhaled CO could be used for the therapy, there are
considerable concerns to apply CO as in vivo treatment. To
minimize the concerns for the possible adverse effects
associating with in vivo CO inhalation, we have recently
developed the ex vivo organ-targeted CO delivery method by
perfusing and storing excised grafts with CO-bubbled
preservation solution before transplantation. Using the
intestinal transplantation model, we showed that ex vivo
delivered CO could ameliorate intestinal I/R injury following
prolonged cold ischemia.21 In the current study using the
kidney transplant model, we confirmed that gaseous CO in
UW preservation solution could be effectively delivered to
excised kidney grafts, prevent renal I/R injury, and improve
renal graft function and survival. The beneficial effects of
ex vivo delivered CO associated with the inhibition of CYP
degradation and heme release in kidney grafts and amelio-
ration of oxidative injuries.
In the bloodless ex vivo condition specifically occurring
in a transplant setting, there is no CO binding to hemoglobin
that is typically seen with inhaled CO in the living animal.
Therefore, CO could bind more efficiently to target mole-
cules, most likely heme proteins, without forming carboxy-
hemoglobin. Thus, ex vivo organ-targeted CO delivery
method might involve mechanisms of action different from
those of the inhalation delivery method.
As CYPs are known to play critical roles in I/R injury
associated with renal transplantation,30,31 we tested our
hypothesis in this study that CO binding to heme moiety of
CYP, in advance, can stabilize and protect CYP from
degradation caused by oxidative attack initiated by reper-
fusion. As the binding activity of CO may not be CYP
specific, CO also may bind to various heme proteins in the
kidney grafts. However, as the kidney is richly endowed with
CYP particularly in the proximal tubules, CO in UW could
effectively bind to CYP during cold storage of the kidney
grafts. In fact, the study demonstrated that excised kidney
grafts exposed to CO during the cold preservation period
could preserve CYP, decrease free heme release, and maintain
normal intracellular heme concentration and metabolism. In
contrast, in untreated grafts, intracellular heme metabolism
was shifted towards heme catabolism due to a large increase
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Figure 6 | CO improved renal graft function. (a) Ischemia/
reperfusion (I/R) injury resulted in progressive deterioration of
renal function determined by creatinine clearance (CCr) at 28 days
after transplantation of kidney grafts stored in control UW.
CCr levels were significantly improved when kidney grafts were
stored in UW containing CO (COUW; *Po0.05 vs UW; n¼ 13–15).
(b) Protein excretion at 28 days after transplantation was
significantly lower in kidney grafts stored in COUW compared to
those in control UW (*Po0.05 vs UW; n¼ 13–15). (c) The recipients
with the grafts stored in control UW gradually lost body weight by
28 days after kidney transplantation (KTx). On the other hand,
CO treatment significantly enhanced recipient body weight gain
(n¼ 13–15). (d) In correlation to improved renal functions,
recipient animal survival was significantly prolonged with ex vivo
delivered CO in UW (n¼ 13–15; Kaplan–Meyer; log-rank test;
Po0.05 UW vs COUW).
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of intracellular heme concentration. Prevention of CYP
degradation could be the result mediated by other mechan-
isms. As kidney grafts stored in UW with CO showed the
downregulation of inflammatory mediators such as TNFa
and IL-6, the inhibition of proinflammatory responses could
be a direct effect of CO. Thus preventing oxidative stress and
the preservation of the CYP content could be an indirect
effect of CO on CYP. However, previous reports using CYP
inhibitors such as cimetidine or piperonyl butoxide show that
CYP degradation and detrimental heme/iron increase from
the organ during I/R injury are inhibited by these drugs due
to their binding to heme and CYP stabilization.32,33 It is also
known that hemoglobin becomes more stable and resistant
against oxidative stress when oxygen binds to hemoglobin
and forms oxyhemoglobin.34 Although further studies will be
necessary to confirm the actual binding site of CO, it is
tempting to conceive that CO-binding to heme moiety of
renal CYP could prevent CYP degradation and block heme/
iron release during kidney I/R injury.
Another possible action of CO on CYP might be an
inhibition of CYP’s enzymatic activities.35 CYPs act as a
monooxygenase and can generate detrimental ROS including
hydrogen peroxide and superoxide anion during the nicotin-
amide adenine dinucleotide phosphate-dependent electron
transfer.36 In addition, CYPs contribute to the metabolization
of arachidonic acid and generation of vasoconstrictor
eicosanoids, which are known to elicit vasoconstriction
of the graft vasculature during I/R injury.37,38 Thus, an
inhibition of CYP enzymatic activities by CO may lead to
reduced ROS generation and improved graft microcircula-
tion. However, considering that significant amount of CYP is
degraded during I/R injury, the inhibitions of these CYP
enzymatic activities by CO are unlikely to play major roles in
I/R injury process.9
It needs to be determined if optimum concentrations of
CO in UW preservation solution can be more effective for
kidney or other organ transplantation. Using 5% gaseous CO
in this study, CO solubility reached 40.6 mmol/l, which
appeared to be effective for KTx experiments. This CO
concentration was chosen based on the previous studies using
CO-releasing molecules.39,40 These reports showed that
cardiomyocytes and renal vascular system were protected
against oxidative stress at CO concentrations of 10–50 mmol/l
in the perfusate containing CO-releasing molecules. Future
studies are warranted to determine if a higher concentration
of CO may bring additional protections against renal I/R
injury.
In conclusion, our results demonstrated that renal CYPs
were degraded during I/R injury, followed by an increase of
intracellular free heme and oxidative injury of the kidney
grafts. The perfusion with and storage in the CO-supple-
mented UW solution prevented CYP degradation and
ameliorated transplant-induced renal graft I/R injury.
Ex vivo organ-targeted CO delivery is an innovative,
attractive, and simple strategy, which can be applicable in
clinical practice. Further, ex vivo CO delivery provides a
unique setting to analyze the functional mechanisms of CO’s
protective effects in the whole organ system.
MATERIALS AND METHODS
CO supplementation to the UW solution
UW solution (Viaspan, Du Pont, Wilmington, DE, USA) was
vigorously bubbled for 5 min at 4 1C with compressed 5% CO gas
mixed in air (PRAXAIR, Danbury, CT, USA) under sterile
conditions in the hume hood. The solubility of CO was determined
using TRI lyzer (Taiyo, Osaka, Japan).
Measurement of tissue CO content
Tissue CO content was measured using a method as previously
described.41 Briefly, 1 ml of homogenized kidney tissue and 3 ml of
phthalate solution (pH 4.01) was transferred into the vacuum tube
and 0.5 ml of potassium ferricyanide (Sigma, St Louis, MO, USA)
was added. The solution was mixed vigorously to release CO from
the tissue homogenate at room temperature. Gas phase (1 ml) was
taken into 10 ml vacuum tube, and released CO was measured by
TRI lyzer. Results were expressed as CO (pmol) per mg tissue
weight.
Animals
Inbred male LEW (RT.1l) rats weighing 200–250 g were purchased
from Harlan Sprague Dawley Inc. (Indianapolis, IN, USA). Animals
were maintained in laminar flow cages in the animal facility at the
University of Pittsburgh with a standard diet and water supplied
ad libitum. All procedures were performed according to the guide-
lines of the Institutional Animal Care and Use Committee at the
University of Pittsburgh and the National Research Council’s Guide
for the Humane Care and Use of Laboratory Animals.
Kidney transplantation
Orthotopic KTx was performed using a previously described
technique.27,42,43 In short, after intravenous heparinization
(300 U), the donor left kidney was removed with the left renal
artery and a short aortic segment, and the left renal vein with a
patch of vena cava. The excised graft was flushed with and preserved
in UW or CO-bubbled UW at 4 1C for 24 h. After recipient’s left
nephrectomy, the kidney graft was orthotopically transplanted into
syngeneic recipient by end-to-side microvascular anastomoses
between graft aorta and recipient infrarenal abdominal aorta, and
between graft renal vein and recipient infrarenal vena cava with 10-0
suture. End-to-end ureteral anastomosis was performed using 10-0
suture. Recipient animals were given 20 mg prophylactic cefaman-
dole nafate immediately after surgery and for 3 days postoperatively.
The remaining right native kidney was removed 10 days after KTx
for the experiments assessing renal functions. The recipients were
weighted every day for the first 2 weeks and at least twice a week
thereafter. We found that B10% of recipients died of surgical
complications such as bowel obstruction and stenosis of ureter
anastomosis, and those recipients were excluded from the study.
Experimental groups
Three groups of animals were examined: unoperated normal LEW
control, control recipients with the grafts preserved in control UW
for 24 h, and the recipients with the grafts stored in CO containing
UW for 24 h. Recipients were killed at 1, 3, 6, 24 h, or 28 days after
KTx to analyze the early events after I/R injury. In additional sets of
experiments, recipient animals were followed for 100 days to assess
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renal graft function and animal survival. Graft kidney samples were
obtained and fixed in 10% buffered formalin, or snap frozen and
stored at 80 1C until they were analyzed.
Renal functions
Plasma was obtained from blood samples, and plasma creatinine
levels were measured using a Beckman autoanalyzer (Beckman
Instruments, Fullerton, CA, USA). Protein and creatinine levels in
24 h urine samples were determined after KTx using the metabolic
cage system. Formula creatinine clearance (CCr; ml/min)¼
(U[Cr] urine volume)/(P[Cr] time), where U[Cr] is urinary
creatinine (mg per 100 ml), urine volume is in milliliters, and P[Cr]
is plasma creatinine (mg per 100 ml).
Histopathology and immunohistochemistry
Kidney graft tissues were fixed in 10% formalin, embedded in
paraffin, sectioned into 6 mm thickness, and stained with hematox-
ylin and eosin. For the detection of macrophages, sections were
incubated with monoclonal anti-rat CD68 (ED1, 1:200; Serotec,
Raleigh, NC, USA), followed by LSABþ horseradish peroxidase
(DAKO, Carpinteria, CA, USA). The immune complex was
visualized with 3-amino-9-ethyl carbazole and hematoxylin counter
staining. Positively stained cells were counted in a blind fashion in
10 random cortical HPF 400 per section.
RNA extraction and SYBR Green real time RT-PCR
RNA was isolated from the rat tissues using Tri-Reagent (Sigma)
according to the manufacturer’s protocol. One microgram of RNA
from each sample was used for reverse transcription with an oligo
dT (Life Technologies, Grand Island, NY, USA) and a Superscript II
(Life Technologies) to generate first-strand cDNA. PCR reaction
mixture was prepared using SYBR Green PCR Master Mix (PE
Applied Biosystems, Foster City, CA, USA). Thermal cycling
conditions were 10 min at 95 1C, followed by 40 cycles of 95 1C
for 15 s and 60 1C for 1 min on an ABI PRISM 7000 Sequence
Detection System (PE Applied Biosystems). Using the manufac-
turer’s software, real-time PCR data were blotted as the DRn
fluorescence signal vs the cycle number. The threshold cycle was
defined as the cycle number at which the DRn crosses this threshold.
The expression of target genes including HO-1, COX-2, IL-6, TNFa,
and Egr-1 was normalized to housekeeping GAPDH mRNA content
and calculated relative to normal kidney control using the
comparative cycle threshold method. To exclude PCR amplification
of contaminating genomic DNA, blank as well as the RT—controls
(samples containing RNA that were not reverse transcribed) were
included in each PCR reaction.
Northern blot for ALAS-1
About 20 mg of RNA was subjected to electrophoresis in a 1.2%
(w/v) agarose gel containing 6.5% (v/v) formaldehyde. After
blotting on a sheet of Bio-Rad Zeta-Probe membrane (Bio-Rad
Laboratories, Richmond, CA, USA), RNA samples were hybridized
with [a-32P]dCTP-labeled ALAS-1 cDNA probe followed by
washing under stringent conditions. The membrane was exposed
to a Fuji Medical radiograph film with an intensifying screen at
70 1C, and autoradiographs were quantified by using an image
scanner (GelPrintTM 2000i, Genomic Solutions, Ann Arbor, MI,
USA) and a computerized image analysis software (Basic Quanti-
fierTM version 3.0, Genomic Solutions) to calculate integrated
optical density.44,45
Western blot analysis
About 50 mg of cytosolic protein was separated by electrophoresis on
8–15% acrylamide sodium dodecyl surface gels and transferred to
nitrocellulose membranes (Scleicher & Schuell, Keene, NH, USA).
For the blocking of nonspecific binding, 5% nonfat dry milk in
phosphate-buffered saline-Tween was added to the membrane for
1 h at room temperature. Membranes were washed in phosphate-
buffered saline-Tween and then incubated overnight with primary
antibodies including rabbit polyclonal anti-b-actin (Sigma) and
rabbit polyclonal anti-human HO-1 (StressGen, Ann Arbor, MI,
USA), followed by incubation with secondary antibody for 45 min.
After repeat washings with phosphate-buffered saline-Tween,
membranes were developed with the SuperSignal detection
systems (Pierce Chemical, Rockford, IL, USA) and exposed to film.
The band intensities were quantified by NIH Image analysis
software.
Tissue CYP content
CYP content was measured as previously described.44,46 In brief,
snap-frozen kidney samples were homogenized in three volumes
of 1.15% KCl and centrifuged at 10,000 g for 30 min at 4 1C,
followed by 104,000 g centrifugation of the supernatant for 60 min
at 4 1C, to obtain the microsomal fraction as a pellet.47 The pellet
was resuspended in 0.1 M potassium phosphate buffer (pH 7.4)
containing 10% glycerol. Microsomal CYP content was determined
from CO-difference spectrum followed by CO bubbling forB1 min.
The peak absorbance at 450 nm was measured and the amount
of CYP was determined by using the extinction coefficient of
91 mM/cm.
Tissue heme concentration
Microsomal fractions were obtained from frozen kidney graft tissues
as described above and used for the measurement of heme
concentration by the pyridine hemochromogen method.48–50 Heme
concentration was expressed as nmol per mg of protein.
Assessment of the oxidative stress
Tissue MDA level, an indicator of oxidative stress in cells and tissues,
was assessed using BIOXYTECH MDA-586 kit (OxisResearch,
Portland, OR, USA). Kidney tissue samples were homogenized in
the buffer (pH 7.9) containing 5 mM butylated hydroxytoluene to
prevent sample oxidation and stored at 80 1C. Once all samples
were collected, they were thawed on ice and 10mg of probucol were
added to further minimize the oxidative reactions, then N-methyl-2-
phenylindole in 25% methanol 75% acetonitrile was added to the
supernatants, followed by the addition of 1 HCI with incubation
at 45 1C for 60 min. A standard curve using 1,1,3,3-tetramethoxy-
propane that generates free MDA during the acid hydrolysis step was
also prepared. All samples and standards were centrifuged (10,000 g,
10 min) and absorbance measured at 586 nm using the Spectronic
Biomate 3 (Thermo Scientific, Waltham, MA, USA) according to the
manufacturer’s protocol.
Statistical analysis
The results were expressed as mean with standard deviation.
Statistical analysis was performed using unpaired Student’s t-test
or analysis of variance where appropriate. A probability level of
Po0.05 was considered to be statistically significant.
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